List of Nesina drug patents

Nesina is owned by Takeda Pharms Usa.

Nesina contains Alogliptin Benzoate.

Nesina has a total of 4 drug patents out of which 0 drug patents have expired.

Nesina was authorised for market use on 25 January, 2013.

Nesina is available in tablet;oral dosage forms.

Nesina can be used as method of treating diabetes comprising administering a compound such as alogliptin, method of treating diabetes comprising administering alogliptin.

The generics of Nesina are possible to be released after 16 June, 2029.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8288539 TAKEDA PHARMS USA Dipeptidyl peptidase inhibitors
Mar, 2025

(2 years from now)

US7807689 TAKEDA PHARMS USA Dipeptidyl peptidase inhibitors
Jun, 2028

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8173663 TAKEDA PHARMS USA Dipeptidyl peptidase inhibitors
Dec, 2025

(2 years from now)

US8697125 TAKEDA PHARMS USA Tablet preparation without causing a tableting trouble
Jun, 2029

(6 years from now)

Drugs and Companies using ALOGLIPTIN BENZOATE ingredient

Market Authorisation Date: 25 January, 2013

Treatment: Method of treating diabetes comprising administering a compound such as alogliptin; Method of treating diabetes comprising administering alogliptin

Dosage: TABLET;ORAL

How can I launch a generic of NESINA before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in